Heranova Lifesciences

The global female infertility market is projected to grow from $1.79 billion in 2024 to $2.19 billion by 2029, driven by increasing infertility rates linked to lifestyle changes, delayed childbearing, and medical conditions such as PCOS and uterine abnormalities. Advancements in fertility treatments, including non-invasive diagnostics and telemedicine, are shaping the market. With Europe leading in market share and Asia-Pacific emerging as the fastest-growing region, innovation in fertility preservation and diagnostic technologies is a key focus. At Heranova, we are dedicated to transforming women’s health with innovative, non-invasive solutions. Our blood-based test, HerResolve, is designed to improve early detection of #endometriosis, a condition that contributes to infertility. As the need for advanced reproductive health solutions grows, Heranova remains at the forefront of accessible and effective diagnostics. Learn more at Heranova.com #FemaleInfertility #Heranova #HerResolve #WomensHealth #Endometriosistest

A new study has successfully developed eutopic and ectopic endometrial organoid models to better understand the pathophysiology of ovarian #endometriosis. These 3D organoids closely mimic the original tissue, maintaining key histological and genetic characteristics, and respond differently to estrogen and progesterone. This breakthrough provides a robust in vitro model for studying endometriosis, testing drug interventions, and exploring personalized treatment strategies. Read the full study in Nature Magazine here: https://bit.ly/4hYTMwh At Heranova, we are committed to advancing non-invasive diagnostic solutions for endometriosis. Our blood-based test, HerResolve, aims to transform early detection and improve patient outcomes. Innovations like these organoid models reinforce the urgent need for better diagnostic and treatment options in women’s health. Learn more at Heranova.com #EndometriosisResearch #Heranova #HerResolve #WomensHealth

Enrollment is open for Heranova's Early Access Program for HerResolve—a non-invasive, blood-based diagnostic test designed to accurately detect #endometriosis in symptomatic women. Fertility clinics and OB/GYN practices are invited to join this innovative initiative to enhance diagnostic accuracy and improve patient care. To learn more about how your practice can join this program and help transform endometriosis detection, visit heranova.com/early-access.? #Heranova #HerResolve #EarlyAccess #WomensHealth #EndometriosisTest #EarlyDetection #ReproductiveHealth

#Endometriosis is a condition where tissue similar to the uterine lining grows outside the uterus, leading to severe cramps, pelvic pain, and irregular periods. Due to overlapping symptoms with other conditions like IBS, ovarian cysts, and pelvic inflammatory disease, misdiagnoses are common, with many patients waiting up to 10 years for an accurate diagnosis. Find out what other conditions are commonly misdiagnosed as endometriosis as well as why endometriosis can be difficult for clinicians to diagnose in this article from Health.com: https://bit.ly/3QQLElD Heranova is at the forefront of developing non-invasive diagnostic tests like HerResolve, our blood-based test to detect endometriosis- offering a promising solution to reduce misdiagnoses, shorten diagnostic delays, and eliminate the need for costly, risky surgical procedures. Learn more at Heranova.com #Heranova #HerResolve #WomensHealth #WomensHealthGap #EndometriosisTest #EarlyDetection #ReproductiveHealth #MisDiagnosis

Women’s health is emerging as a high-growth investment frontier. Recent analysis, including the newly released Women's Health Access Matters (WHAM) report, shows that targeted funding—such as $350 million in research—could yield returns up to $14 billion, and closing the 25% gap in women’s health could add $1 trillion annually to global GDP by 2040. With venture investments projected to hit $66B by 2033, there’s a clear economic and social imperative to address historical underinvestment. Read more in this article from Forbes: https://bit.ly/4gU9TK9 by Sylvana Q. Sinha, Esq. Heranova is spearheading innovative research and diagnostic solutions for #endometriosis—a condition affecting 1 in 10 women. Our work is focused on addressing the unique challenges of this disease and advancing care to improve quality of life for countless women with a suite of breakthrough diagnostic tools including HerResolve- a non-invasive, blood-based test for detecting endometriosis in symptomatic women. Learn more at Heranova.com #Heranova #HerResolve #WomensHealth #WomensHealthGap #EndometriosisTest #EarlyDetection #ReproductiveHealth #WHAMreport #BiotechInvesting

Research published by Cell Press sheds light on a new prospective therapeutic target for #endometriosis, revealing that endometrial cells growing outside the uterus interact with ovarian and immune cells through the WNT5A signaling pathway, potentially sustaining lesion growth. Read the full study here: bit.ly/4hUv9A8? At Heranova, we are dedicated to advancing women's health through HerResolve, our non-invasive, blood-based diagnostic for endometriosis. As research evolves, accurate and accessible diagnosis remains essential in improving care and outcomes for women with this complex condition. Learn more at Heranova.com? #Heranova #HerResolve #WomensHealth #Endometriosistest #Earlydetection?#CellGenomics

By 2030, demand for OB-GYNs is expected to exceed supply by 11%, driven by a 4% increase in demand and a 7% decrease in practicing providers. This growing gap in women's healthcare highlights the need for innovative diagnostic solutions that can ease the burden on healthcare providers while ensuring patients receive timely, accurate care. At Heranova, we are committed to raising the standard of care through HerResolve, our non-invasive, blood-based diagnostic solution for #endometriosis. As access to specialists becomes increasingly strained, HerResolve offers a reliable and efficient path to diagnosis, helping women receive the care they need without unnecessary delays. Learn more at heranova.com #Heranova #HerResolve #WomensHealth #Endometriosistest #EarlyDetection?#WomensHealthGap

This Valentine’s Day, let's celebrate love, health, and the well-being of women everywhere. For the millions affected by #endometriosis, self-care and early detection are essential to reclaiming quality of life. At Heranova, we are dedicated to advancing women’s health through the development of cutting-edge tools like HerResolve, our innovative, non-invasive blood-based diagnostic for endometriosis. Because every woman deserves to live without the burden of delayed diagnosis and unanswered pain. This Valentine’s Day, show love by supporting awareness, research, and solutions that make a difference. Learn more at Heranova.com #Heranova #HerResolve #WomensHealth #Valentinesday #Endometriosistest

New research is reshaping our understanding of #endometriosis by integrating single-cell and multi-omic data with clinical insights. This comprehensive approach is uncovering distinct disease subtypes, advancing diagnostics, and informing novel, personalized treatments. While surgical identification remains the gold standard for diagnosis, AI-driven applications and molecular profiling are poised to revolutionize early detection and disease classification. The future of endometriosis care lies in multidisciplinary collaboration, data integration, and cutting-edge computational tools. Read the full study in Nature Magazine here: https://bit.ly/4aLxfA9 At Heranova, we are committed to advancing non-invasive diagnostics for endometriosis. Our flagship solution, HerResolve, leverages blood-based biomarkers to provide earlier, more accurate detection, helping patients receive timely and effective care. #Heranova #HerResolve #WomensHealth #Endometriosistest #Earlydetection?

A study published in JAMA Psychiatry highlights a significant association between traumatic experiences—especially contact, emotional, physical, and sexual traumas—and #endometriosis. Genetic analyses further reveal a shared genetic predisposition between endometriosis and trauma-related conditions, including PTSD. While genetic risk and trauma appear to act independently, their assessment could help identify individuals at higher risk for developing the disease. These findings emphasize the need for a comprehensive, multidisciplinary approach to endometriosis care. Read the full study here: https://bit.ly/4gtlVtF At Heranova, we are dedicated to transforming endometriosis diagnostics through non-invasive solutions. Our pioneering test, HerResolve, utilizes blood-based biomarkers to enable earlier and more precise detection, ensuring patients receive the care they need without unnecessary delays. Learn more at Heranova.com #Heranova #HerResolve #WomensHealth #Endometriosistest #Earlydetection